Immediate Hazard and Urgent Safety Measures

Part of Principal Investigator (PI) Training: Safety Reporting and Unblinding.

About 4 minutes. Free, in your language, no account needed.

Why this matters

Everything else in this course tells you not to depart from the protocol. This lesson is the exception, and it exists because a protocol is written months in advance by people who are not in the room with your patient.

Investigators get this wrong in both directions: hesitating to act because the protocol does not permit it, or acting and then failing to notify. The guideline is comfortable with the first half. It is strict about the second.

The permission

Section 2.5.4 permits the investigator to deviate from the protocol to eliminate an immediate hazard to trial participants, without prior agreement from the sponsor and without prior IRB or IEC approval.

Read alongside Principle 1.5 — the rights, safety and wellbeing of participants prevail over the interests of science and society — this is unambiguous. You are not required to obtain permission before protecting a participant from immediate danger. You are required to tell people afterwards.

Examples that plainly fall inside it: withholding a dose from a deteriorating participant, giving a prohibited medication that is clinically necessary in an emergency, admitting someone the protocol contemplated managing as an outpatient, discontinuing investigational product for safety before the protocol's stopping rule is technically met.

The boundaries

Two limits keep this from becoming a general license, and both were introduced in Module 4.

It removes a danger; it does not create an opportunity. Enrolling somebody who does not meet eligibility is never an immediate-hazard deviation, because declining to enroll them harms nobody.

The hazard is immediate. Something that can safely wait for a telephone call to the sponsor should wait for one. "Immediate" is a clinical judgment, and it is judged on what you reasonably believed at the time — which is another reason to write the reasoning down while it is fresh.

The notification that must follow

Section 2.5.5 requires prompt notification. The deviation implemented, the reasons for it, and any proposed protocol amendment are communicated to the sponsor and, as required by applicable regulatory requirements, to the IRB or IEC and the regulatory authorities. Section 2.4 reinforces the IRB/IEC route for deviations implemented to eliminate an immediate hazard.

A workable sequence:

1. Act. Protect the participant.
2. Document the same day — in the source record, contemporaneously: what the hazard was, what you did, what you believed at the time.
3. Notify the sponsor promptly, typically the same or next working day.
4. Notify the IRB or IEC per their requirements — many committees have a specific route and a specific window for urgent safety measures.
5. Ask whether it should change the protocol. If this hazard could recur for other participants, it is an amendment conversation, not a one-off.

Step five is the one that separates a competent site from a good one. A deviation that protected one participant and changed nothing may leave the next participant exposed.

When it is bigger than one participant

Sometimes the right response is not a deviation but a halt. Section 2.6 covers premature termination and suspension, and it distributes the duties.

• §2.6.1 — where the trial is terminated or suspended, the investigator promptly informs the participants, ensures appropriate therapy and follow-up for them, and where required by applicable regulatory requirements informs the regulatory authorities.
• §2.6.2 — where the investigator terminates or suspends without prior agreement from the sponsor, the investigator informs the institution as applicable, and the investigator or institution promptly informs the sponsor and the IRB/IEC with a detailed written explanation.
• §2.6.3 — where the sponsor terminates or suspends, notification of the IRB/IEC and, where required, the regulatory authorities is a shared duty.
• §2.6.4 — where the IRB or IEC withdraws its approval or favorable opinion, the investigator or institution informs the sponsor with a detailed written explanation.

You can suspend enrollment at your own site. It is a serious step and there are circumstances that warrant it — a safety signal you cannot reconcile, the loss of a facility or a key staff member, a pattern of deviations you cannot control. Doing it deliberately, with a written explanation, is far better than continuing a trial you cannot conduct properly.

Key takeaways

• §2.5.4 permits deviation without prior approval to eliminate an immediate hazard; Principle 1.5 is the reason.
• The exception removes danger, never creates opportunity, and does not extend to anything that could safely wait.
• §2.5.5 and §2.4 require prompt notification to the sponsor and, as required, the IRB/IEC and authorities — and a question about whether the protocol should change.
• §2.6.1–§2.6.4 distribute the duties on termination or suspension; participants are informed first and their ongoing care ensured.